Skip to main content
. 2025 Jan 7;31(1):101198. doi: 10.3748/wjg.v31.i1.101198

Table 3.

Correlation between expression of ASH1L and clinicopathological characteristics

Variable
High expression (n = 44)
Low expression (n = 67)
P value
Gender (M/F) 37/7 56/11 0.944
Age (year) 54.73 ± 8.56 54.63 ± 9.67 0.814
Hepatitis (HBV/HCV/none) 36/4/4 52/9/5 0.487
Cirrhosis (Y/N) 32/12 64/2 0.25
MELD score 7.67 (5.57-9.65) 6.62 (5.43-8.09) 0.071
Number of tumors (multiple/single) 30/14 33/34 0.05
Maximum diameter of tumor (cm) 3.50 (2.00-6.00) 3.00 (2.00-6.00) 0.954
Satellite cooker (Y/N) 12/32 11/56 0.169
MVI (Y/N) 16/28 12/55 0.029
Tumor differentiation (well/moderate/poor/undifferentiation) 0/28/15/1 1/40/19/7 0.649
Clinicopathological stage (I/II/III/IV) 7/12/25/0 20/22/25/0 0.032
Relapse states (N/Y) 22/22 47/22 0.002
Vital states (alive/dead) 25/19 56/11 0.033

Y: Yes; N: No; M: Male; F: Female; MELD: Model for end-stage liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus.